Holen Sie sich die Stockscreener-App
69.97
0.43%
-0.30
Handel nachbörslich:
69.41
-0.56
-0.80%
Schlusskurs vom Vortag:
$70.27
Offen:
$70
24-Stunden-Volumen:
1.69M
Relative Volume:
0.70
Marktkapitalisierung:
$11.15B
Einnahmen:
$705.14M
Nettoeinkommen (Verlust:
$-453.90M
KGV:
-23.02
EPS:
-3.04
Netto-Cashflow:
$-551.29M
1W Leistung:
+1.19%
1M Leistung:
+9.33%
6M Leistung:
+161.96%
1J Leistung:
+84.37%
1-Tages-Spanne:
$69.40
$70.49
1-Wochen-Bereich:
$67.95
$71.87
52-Wochen-Spanne:
$23.95
$71.87
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Vergleichen Sie IONS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
69.97 | 11.20B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Hochstufung | Goldman | Sell → Neutral |
| 2025-09-03 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Can technical indicators confirm Ionis Pharmaceuticals Inc.’s reversalProduct Launch & Safe Entry Trade Signal Reports - newser.com
Will Ionis Pharmaceuticals Inc. price bounce be sustainableIndex Update & Fast Momentum Entry Tips - newser.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
How Recent Milestones Are Shaping the Outlook and Valuation for Ionis Pharmaceuticals - Yahoo Finance
A Look at Ionis Pharmaceuticals's Valuation Following Pipeline Progress and Strong Innovation Day Updates - Yahoo Finance
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $78.00 at Needham & Company LLC - MarketBeat
Eric Swayze Sells 6,849 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $937,375.34 in Stock - MarketBeat
Brett Monia Sells 437 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Ionis Poised To Break Even In 2028 Fueled By A Cadence Of Launches - insights.citeline.com
Ionis Pharmaceuticals stock maintains Buy rating at TD Cowen on pipeline strength - Investing.com Nigeria
News impact scoring models applied to Ionis Pharmaceuticals Inc.July 2025 Short Interest & Capital Efficiency Focused Strategies - newser.com
Ionis Pharmaceuticals EVP Swayze sells $472k in stock By Investing.com - Investing.com Canada
Ionis Pharmaceuticals (NASDAQ:IONS) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Castle Rock Wealth Management LLC Invests $215,000 in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by DAVENPORT & Co LLC - MarketBeat
Ionis Pharmaceuticals’ SWOT analysis: RNA pioneer’s stock faces pivotal year By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals EVP O’Neil sells $937k in IONS stock By Investing.com - Investing.com South Africa
Ionis Pharma EVP Baroldi sells $112k in shares By Investing.com - Investing.com Canada
Insider Sell: Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
Ionis Pharmaceuticals EVP O’Neil sells $937k in IONS stock - Investing.com Nigeria
Oppenheimer Maintains Ionis Pharmaceuticals (IONS) Outperform Recommendation - Nasdaq
Ionis Pharma EVP Baroldi sells $112k in shares - Investing.com India
Ionis Pharmaceuticals EVP Swayze sells $472k in stock - Investing.com India
Ionis Pharmaceuticals’ SWOT analysis: RNA pioneer’s stock faces pivotal year - Investing.com
Ionis Pharmaceuticals stock hits 52-week high at 70.49 USD By Investing.com - Investing.com Nigeria
Needham Raises Price Target on Ionis Pharmaceuticals (IONS) to $78 | IONS Stock News - GuruFocus
Oppenheimer Raises Ionis Pharmaceuticals (IONS) Price Target to $90 | IONS Stock News - GuruFocus
JP Morgan Boosts Ionis Pharmaceuticals (IONS) with Upgrade and P - GuruFocus
Ionis upgraded at JP Morgan on expanding Tryngolza market, pipeline - Seeking Alpha
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook - FinancialContent
Is Ionis Pharmaceuticals Inc ISI a good long term investmentMid Cap Growth Trends & Discover Strategies with Fellow Traders - earlytimes.in
JP Morgan Upgrades Ionis Pharmaceuticals (IONS) to Overweight, R - GuruFocus
Retinitis Pigmentosa Pipeline 2025: Comprehensive Clinical - openPR.com
HC Wainwright Reiterates Buy Rating for Ionis Pharmaceuticals (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded to Overweight at JPMorgan Chase & Co. - MarketBeat
JPMorgan Upgrades Ionis Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $80 From $49 - MarketScreener
HC Wainwright Reiterates Buy Rating for Ionis Pharmaceuticals (I - GuruFocus
Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day - BioSpace
Ionis Pharmaceuticals Hits New 52-Week High of $70.14 - Markets Mojo
Transcript : Ionis Pharmaceuticals, Inc.Shareholder/Analyst Call - MarketScreener
Ionis Pharmaceuticals : IONS Innovation Day 2025 FINAL - MarketScreener
Ionis outlines growth strategy with four launches planned by 2026 - Investing.com Nigeria
Ionis Pharmaceuticals Hits New 52-Week High of $69.25 - Markets Mojo
Ionis Pharmaceuticals (NASDAQ:IONS) Reaches New 12-Month HighHere's What Happened - MarketBeat
Ionis Pharmaceuticals (IONS): Stifel Raises Price Target to $67 - GuruFocus
Published on: 2025-10-06 08:01:09 - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock a fit for income portfoliosNew Guidance & Smart Investment Allocation Insights - newser.com
Using fundamentals and technicals on Ionis Pharmaceuticals Inc.July 2025 Breakouts & Safe Capital Growth Tips - newser.com
Is Ionis Pharmaceuticals Inc. building a consolidation base2025 AllTime Highs & Safe Capital Growth Tips - newser.com
Should you hold or exit Ionis Pharmaceuticals Inc. nowBull Run & Fast Momentum Entry Tips - newser.com
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ionis Pharmaceuticals Inc-Aktie (IONS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| O'NEIL PATRICK R. | EVP CLO & General Counsel |
Oct 06 '25 |
Option Exercise |
52.87 |
10,200 |
539,274 |
67,330 |
| O'NEIL PATRICK R. | EVP CLO & General Counsel |
Oct 06 '25 |
Sale |
69.74 |
13,441 |
937,338 |
53,889 |
| Monia Brett P | Chief Executive Officer |
Oct 06 '25 |
Sale |
69.26 |
437 |
30,268 |
179,572 |
| Baroldi Joseph | EVP, Chief Business Officer |
Oct 06 '25 |
Sale |
69.37 |
1,625 |
112,725 |
30,301 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):